Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...

Piper Sandler、Chardan Capital Markets和花旗都对这一发展做出了反应。Piper Sandler将Arrowhead的12个月目标价从之前的$62下调至$45，同时维持超配评级。Chardan Capital Markets维持对Arrowhead的买入评级和$60.00的股票目标价。花旗则略微下调目标价，从$27.00降至$26.00，同时保持对该股票的中性立场 ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.